Abstract

Abstract Indolyl-pyridinyl-propenones (a subclass of synthetic indole-based chalcones) have been shown to induce a novel form of cell death termed ‘methuosis’ in glioblastoma and other tumor cell lines. This form of cell death is caspase-independent and involves massive vacuolization of macropinosome and endosome compartments. In the course of structure-activity relationship studies identifying a lead compound, 3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propene-1-one (abbreviated 5-MOMIPP), we discovered that changing the methoxy substitution from the 5-position to the 6-position on the indole ring markedly alters the biological activity of the compound. 6-MOMIPP exhibits potent anti-proliferative and cytotoxic activity in glioblastoma, melanoma and other cancer cell lines at a concentration of 100 nM, nearly two orders of magnitude lower than the maximally effective concentration of 5-MOMIPP. Instead of inducing methuosis, 6-MOMIPP (at > 500 nM) immediately disrupts microtubules, as confirmed by immunofluorescence microscopy. By 24 h the majority of the cells are rounded and arrested in mitosis, and by 48 h cell viability is greatly reduced. The few remaining live cells contain multiple abnormal nuclei. Extensive cell death occurs before activation of caspases 3, 7 and 9 can be detected. Scintillation proximity assays show that 6-MOMIPP competes with 3H-colchicine, but not 3H-vinblastine, for binding to tubulin. Studies aimed at testing the toxicity of 6-MOMIPP in normal cells are in progress, but work with a closely related microtubule-active indole-based chalcone indicates that toxicity is substantially reduced in quiescent human fibroblasts and rat neuronal progenitor cells. Although drugs targeted to microtubules (e.g., Vinca alkaloids and taxanes) are widely used as anti-neoplastic agents, they have shown little efficacy in treating primary or metastatic brain tumors, partly due to limited penetrance of the blood-brain barrier (BBB). Preliminary pharmacokinetic studies in mice show that 6-MOMIPP injected IP can readily cross the BBB, attaining brain concentrations nearly equal to plasma concentrations within 30 min to 1 h. Therefore, these preliminary findings suggest that 6-MOMIPP merits further preclinical evaluation as a potential therapeutic agent for primary and metastatic brain tumors. Supported by NIH grant CA115495 and by the Helen and Harold McMaster Endowment. Citation Format: Shengnan Du, Jeffrey G. Sarver, Christopher J. Trabbic, Paul W. Erhardt, Jean H. Overmeyer, William A. Maltese. A novel microtubule-disrupting indole-based chalcone that induces caspase-independent cell death in glioblastoma and melanoma cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1244.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call